Latest news
Alteogen Returns to Profit in Q2 as Sales Surge 270% - marketscreener.commarketscreener.com · Fri, 07 Aug 2026 04:29:25 GMTAlteogen returns to profit as Keytruda SC sales and platform deals surge - CHOSUNBIZ - ChosunbizChosunbiz · Fri, 07 Aug 2026 02:00:00 GMTAlteogen Signs Up to $365 Million Hybrozyme Licensing Deal for Subcutaneous Biologic - BioPharma APACBioPharma APAC · Fri, 07 Aug 2026 01:06:22 GMTAlteogen signs $365m Hybrozyme licensing deal with pharma company - Pharmaceutical TechnologyPharmaceutical Technology · Thu, 06 Aug 2026 17:23:32 GMTAlteogen signs up to $365 million licensing deal for Hybrozyme drug delivery technology - Indian Pharma PostIndian Pharma Post · Thu, 06 Aug 2026 13:00:00 GMTKorea's Alteogen inks $365 M deal for development and commercialisation of Hybrozyme™-enabled subcutaneous biologic product - BioSpectrum AsiaBioSpectrum Asia · Thu, 06 Aug 2026 12:06:10 GMTAlteogen Licenses Subcutaneous Platform to Undisclosed Global Pharma Company in Deal Worth Up to $365 Million - BioPharm InternationalBioPharm International · Wed, 05 Aug 2026 19:10:58 GMTAlteogen Inks Licensing Pact with Global Pharma Company to Develop, Commercialize Subcutaneous Biologic - Contract PharmaContract Pharma · Wed, 05 Aug 2026 15:57:30 GMT